NICE gives thumbs-up to Amgen bone drug

The U.K.'s cost-effectiveness watchdog has approved Amgen's (AMGN) osteoporosis drug Prolia (denosumab) for routine use by the National Health Service in postmenopausal patients who are at increased risk of osteoporotic bone fractures. Report

Suggested Articles

jnj
Pharma

J&J recalls one lot of talc, and investors wipe away billions

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

by Eric Sagonowsky
Teva headquarters
Manufacturing

Teva recalls tainted Zantac generics in the U.K.

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

by Eric Palmer
Vyndaqel
Marketing

Pfizer's tafamidis poised for 'a decisive beat': analyst

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.

by Angus Liu